Paramax Moves Closer To FDA Approval
Paradigm Medical Industries, Inc. (OTC.PK: PDMI) announced today that it had received notification from its Italian partner, Costruzione Strumenti Oftalmici (CSO), which manufactures the Paramax, that it has provided 26 pages and 24 attachments to the U.S. Food and Drug Administration (FDA) in order to obtain 510(k) approval for the Paramax. This supportive information was submitted to the FDA for review on Monday, May 16, 2011. The Paramax is the next generation of standard ocular eletrophysiology utilized for early glaucoma detection. Paradigm will begin marketing and selling the Paramax in (Read more...)